Begin enrollment in the Phase I/II clinical study of AMT-260
Delivered after the deadline (52 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 1 Aug 2024
- Due
- 30 Sep 2024
- Delivered
- 21 Nov 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“AMT-260 for the treatment of refractory mesial temporal lobe epilepsy (mTLE) – Patient screening in a Phase I/II clinical study has been initiated and enrollment is expected to begin in the third quarter of 2024.”
What we found
Evidence strength A What the grades mean
The company announced the dosing of the first patient in the AMT-260 Phase I/II clinical trial on November 21, 2024, which occurred after the third quarter 2024 deadline.
-
A uniQure N.V. 10-Q filed 2024-11-05
“The first patient has been enrolled into the observational phase of the Phase I/II clinical trial of AMT-260 for the treatment of mTLE. ... enrollment has taken longer than expected.” ✓ confirmed on the page
-
A uniQure N.V. 8-K filed 2024-11-21
“uniQure N.V. (NASDAQ: QURE)... today announced that the first patient has been dosed in the GenTLE Phase I/IIa clinical trial of AMT-260” ✓ confirmed on the page
Market reaction: the shares moved +29.1% against the S&P 500 over the three sessions around the disclosure (4 Nov 2024 to 7 Nov 2024). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- Enrollment in AMT-260 clinical study
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-QURE-001882 · Corrections policy